Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Liver Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Metastatic Liver Cancer - Pipeline Review, H2 2015', provides an overview of the Metastatic Liver Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metastatic Liver Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Metastatic Liver Cancer - Overview 7 Pipeline Products for Metastatic Liver Cancer - Comparative Analysis 8 Metastatic Liver Cancer - Therapeutics under Development by Companies 9 Metastatic Liver Cancer - Therapeutics under Investigation by Universities/Institutes 10 Metastatic Liver Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Metastatic Liver Cancer - Products under Development by Companies 13 Metastatic Liver Cancer - Products under Investigation by Universities/Institutes 14 Metastatic Liver Cancer - Companies Involved in Therapeutics Development 15 AB Science SA 15 Arrowhead Research Corporation 16 Mirna Therapeutics, Inc. 17 Transgene Biotek Limited 18 Metastatic Liver Cancer - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 masitinib - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 MRX-34 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Oncolytic Virus for Liver Metastases and Primary Liver Tumors - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 PSL-001 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 TBL-0404 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Vaccine for Oncology - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Metastatic Liver Cancer - Recent Pipeline Updates 40 Metastatic Liver Cancer - Dormant Projects 51 Metastatic Liver Cancer - Discontinued Products 52 Metastatic Liver Cancer - Product Development Milestones 53 Featured News & Press Releases 53 Jul 02, 2015: AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies 53 Jan 14, 2014: Mirna Therapeutics Reports Expansion of Intellectual Property Estate 55 Jul 24, 2013: PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for Metastatic Liver Cancer, H2 2015 7 Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2015 8 Number of Products under Development by Companies, H2 2015 9 Number of Products under Investigation by Universities/Institutes, H2 2015 10 Comparative Analysis by Clinical Stage Development, H2 2015 11 Comparative Analysis by Early Stage Development, H2 2015 12 Products under Development by Companies, H2 2015 13 Products under Investigation by Universities/Institutes, H2 2015 14 Metastatic Liver Cancer - Pipeline by AB Science SA, H2 2015 15 Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2015 16 Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015 17 Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2015 18 Assessment by Monotherapy Products, H2 2015 19 Number of Products by Stage and Target, H2 2015 21 Number of Products by Stage and Mechanism of Action, H2 2015 23 Number of Products by Stage and Route of Administration, H2 2015 25 Number of Products by Stage and Molecule Type, H2 2015 27 Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2015 40 Metastatic Liver Cancer - Dormant Projects, H2 2015 51 Metastatic Liver Cancer - Discontinued Products, H2 2015 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.